Topiramate augmentation in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial by Zarean, Elham. et al.
Journal of Research in Medical Sciences| October 2014 | 976
Topiramate augmentation in refractory obsessive-
compulsive disorder: A randomized, double-blind, 
placebo-controlled trial
Hamid Afshar, Shahla Akuchekian1, Behzad Mahaky2, Elham Zarean3
Psychosomatic Research Center, Department of Psychiatry, School of Medicine, 1Behavioral Sciences Research Center, Nour Hospital, 
Department of Psychiatry, School of Medicine, 2Department of Biostatistics, 3Behavioral Sciences Research Center, Nour Hospital, 
Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
response,” ≥25% but <35% as “partial response,” and 
<25% as “nonresponse.”[6]
There are lots of strategies to augment the treatment 
response in nonresponsive patients ranging from adding 
cognitive-behavioral therapy[7-9] to pharmacotherapy 
augmentations such as Antipsychotics,[10-13] a combination 
of another SRIs,[14,15] lamotrigine,[16] etc., or even the use 
of neurosurgical procedures.[17] One of the strategies, 
investigate in recent years, to treat the refractory OCD 
has been adding glutamate-modulating agents (GMAs) 
to the existing treatment.
With respect to many neuroimaging[18-20] and glutamate 
concentration studies[21] glutamate may has a role in the 
pathophysiology of OCD. Animal models of OCD and 
also genetic studies provided us additional support; in 
one study McGrath et al. showed that transgenic mice 
with increased glutamate output to the striatum revealed 
a phenotype similar to comorbid OCD and Tourette 
syndrome.[22] Two linkage studies have proposed that 
the gene Solute Carrier Family 1, Member 1 (SLC1A1) 
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a common, 
neuropsychiatric disorder that can have debilitating 
effects on both genders throughout their life. The 
lifetime prevalence of the disorder is about 2-3%.[1]
Although selective serotonin reuptake inhibitors (SSRIs) 
and clomipramine are recommended as first-line 
agents for drug treatment of OCD,[2] it is estimated that 
more than 40-60% of the SSRIs treated population are 
treatment resistant.[3] Treatment-resistant OCD patients 
are described as those who received adequate trials of 
first-line therapies, but a reduction in their Yale-Brown 
Obsessive-Compulsive Scale (Y-BOCS) is <25% or <35% 
with respect to baseline.[4]
An adequate trial of first-line therapies is described as at 
least 10-12 weeks of highest tolerated dose of serotonin 
reuptake inhibitors (SRIs).[5] In another description, 
Pallanti and Quercioli defined treatment response 
stages; 35% or greater reduction in Y-BOCS as “full 
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Background: This study aimed to assess the efficacy of topiramate, a glutamate-modulating agent, in patients with treatment-resistant 
obsessive-compulsive disorder (OCD) as an adjunct to serotonin reuptake inhibitors (SRIs). Materials and Methods: Thirty-eight 
patients with refractory OCD, were randomly assigned to receive topiramate or placebo. This study was designed as a 12 weeks, 
double-blind, placebo-controlled trial. Primary outcome measures were the change in Yale-Brown Obsessive-Compulsive Scale 
(Y-BOCS) score and the rate of treatment response in each group at the study end point. Treatment response was considered as 
25% or more reduction in Y-BOCS score. Results: A total of 13 patients in the topiramate group and 14 ones in the placebo group 
completed the trial. Topiramate-assigned patients showed significantly improved mean Y-BOCS score over time (P < 0.001). Although 
differences between two groups were significant in the Y-BOCS score at the first 2 months (P = 0.01), this was not significant at 
the end of the study (P = 0.10). Changes of Clinical Global Impression (CGI)-Severity of Illness Scale score and CGI-Improvement 
Scale score were not significantly different between two groups (P > 0.05). Treatment response was almost significantly different in 
the topiramate group comparing placebo group (P = 0.054). Mean topiramate dosage was 137.5 mg/day (range, 100-200). Conclusion: 
This study didn’t show efficacy of topiramate as an agent to augment SRIs in treatment-resistant OCD patients.
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that is found in chromosome region 9p24 may contribute 
to OCD. SLC1A1 encodes for the glutamate transporter, 
excitatory amino acid carrier-1 (EAAC1). EAAC1 has a 
central role in preserving normal levels of glutamate in the 
extrasynaptic space and terminating the action of glutamate 
at the synapse.[18] In addition, Arnold PD and Dickel DE, 
showed an interrelation between the glutamate transporter 
gene SLC1A1 and OCD.[23,24]
Until now numerous studies have been designed to 
assess the effect of GMAs such as riluzsole, memantine 
and N-Acetylcysteine as add-on treatment for refractory 
OCD.[5,25-27]
Topiramate is an antiepileptic agent that is effective 
against both partial and generalized seizures and has 
some positive psychotropic effects.[28] Topiramate directly 
inhibits glutamate action through the Amino-3-Hydroxy-
5-Methyl-4-Isoxazole Propanoic Acid 9/kainite subtype 
of glutamate receptors and also potentiate the activity of 
gamma-aminobutyric acid at nonbenzodiazepine sites.[29] 
It means that it has antiglutamatergic effects.
Few studies have been conducted to assess the efficacy 
of adding topiramate to treat refractory OCD. A few case 
reports and a retrospective, open-label case series showed 
some beneficial effects in topiramate augmentation 
for the treatment of resistant OCD.[30,31] In a trial Berlin 
et al. demonstrated that topiramate augmentation may 
be beneficial for compulsions but not obsessions.[32] The 
opposite effects also have been reported on topiramate.[33] 
With respect to these contradictory results and also because 
few randomized clinical trials (RCT) have been conducted in 
this field, we designed a randomized, double-blind, placebo-
controlled clinical study to evaluate the efficacy of topiramate 
in patients with resistant OCD as an adjunct to SRIs.
MATERIALS AND METHODS
Study design
The study was designed as a 12 weeks randomized, double-
blind, placebo-controlled clinical trial. The patients were 
recruited from psychosomatic and psychiatric clinics 
affiliated to the Isfahan University of Medical Science from 
February 2013 to November 2013.
We screened 60 patients totally using convenience sampling 
(based on exclusion and inclusion criteria). Finally, 
38 eligible patients were randomly allocated to either 
the topiramate or placebo group using random number 
generator software [Figure 1]. To contemplate blindness, 
the researcher who assigned patients had no role in the 
treatment or collection of data, and the examiner who was 
responsible for the treatment of patients and filling Clinical 
Global Impression (CGI) scale was not notified about 
patients’ medication.
The study protocol was explained to patients, and informed 
consent was obtained. This trial was approved by the Ethics 
Committee of the Isfahan University of Medical Science and 
registered in the Iranian Registry of Clinical Trials (www.
irct.ir, identifier: IRCT 2013012312252N1). All phases of this 
study were performed about the declaration of Helsinki 
ethical principles for medical research involving human 
subjects.
Participants
Men and women aged 22-60 years with refractory OCD and 
without having any exclusion criteria.
Patients were diagnosed by an experienced psychiatrist 
using Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, third revision (DSM-IV-TR) 
criteria for OCD and comorbid conditions.
Exclusion criteria were any uncontrolled medical conditions 
(like hypertension, diabetes mellitus, etc.), any primary 
diagnosis of psychotic or bipolar disorder, substance 
abuse or dependence, current pregnancy or lactation or an 
intention to get pregnant during the period of intervention, 
convulsive disorders, suicidal thoughts, previous use 
Figure 1: Study profile
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of topiramate and past history of having renal stone or 
being under psychotherapy. From 38 patients that were 
recruited, seven ones dropped out of the study because of 
unwillingness or side effects [Figure 1].
Treatment failure is considered as a Y-BOCS score of 16 
or greater after at least 12 weeks of SRI treatment with an 
adequate dose.
Intervention
Patients in the intervention group received topiramate with 
an initial dose of 25 mg/day which increased 25 mg weekly 
to a maximum dose of 200 mg/day with respect to patients’ 
tolerance. Another group received matching placebos. SRIs 
treatment continued during the study with the same dose 
as the preintervention phase. Placebo tablets were made 
in Arya Pharmaceutical Company (Tehran, Iran) with 
the same shape and color as topiramate tablets. Dosage 
increase was performed similarly in each of two groups. 
The mean topiramate dosage was 137.5 mg/day (range, 
100-200 mg/day).
Efficacy measures
The patients were interviewed at baseline and every 
4 weeks by the psychiatrist using the semi-structural clinical 
interview of DSM-IV-TR and also assessed via Y-BOCS 
questionnaire. Symptoms severity was evaluated by the 
CGI Severity of Illness (CGI-S) scale at the beginning and 
on weeks 8 and 12. Clinical improvement on weeks 8 and 
12 was evaluated via CGI Improvement (CGI-I) scale.
The primary efficacy measures were the changes in the 
Y-BOCS and also the response rate in each of two groups at 
the end point. We considered treatment response as ≥25% 
reduction in the Y-BOCS score.
The Y-BOCS is a 10 items reliable clinician-rated instrument. 
Each item is rated from 0 to 4 so total score ranges from 0 
to 40. Each of CGI-S and CGI-I scales has a 7-point scale.
Safety assessments
All patients were screened through a physical examination 
and medical history (with special attention to not having 
past personal or family history of renal stone) before the 
study. To evaluate safety and tolerability of topiramate, 
the researcher asked the patients to report adverse effects, 
and also they were assessed through rates of premature 
termination due to adverse events.
Statistical analysis
Baseline demographic characteristics are shown as mean 
± standard deviation (SD) or number (%). Independent 
samples t-test and Fisher’s exact test were used to compare 
quantitative and qualitative variables between topiramate 
and placebo groups respectively. To assess the significance 
of differences in the rate of adverse events between the two 
groups the Fisher’s exact test was used.
To evaluate differences of Y-BOCS score in weeks 0, 4, 8 and 
12 and differences of CGI-S in weeks 0, 8 and 12 repeated 
measures analysis of variance (ANOVA) was used. It was 
also performed to evaluate the effect of treatment, sex and 
duration of illness on the changes over time. For CGI-I 
paired-samples t-test was used to compare the differences 
in two measurements. Furthermore, Independent samples 
t-test was performed to compare CGI-I changes between 
the two groups.
The Statistical Package for Social Sciences software (SPSS) 
version 19.0 (SPSS Inc., Chicago, IL, USA) were used for 
analyses. P < 0.05 was considered as statistically significant.
RESULTS
Patient’s characteristics
The mean ± SD of age for the 38 patients was 34.53 ± 8.59 years 
(range, 22-60 years). Thirty-six patients (93.5%) were women, 
and the remaining were men. The patients were recruited in 
the topiramate (n = 19) or placebo (n = 19) group. There were 
no statistically significant differences respecting age, sex, 
marital status and duration of illness between the groups 
[Table 1]. Similarly, The Y-BOCS and CGI-S scale scores were 
comparable at the beginning of the study.
Three patients (15.7%) from topiramate group and four 
patients (21.05%) from the placebo group withdrew the 
trial before week 4. One patient from the placebo group 
and three ones from topiramate group left the study at the 
end of month 2 [Figure 1].
Efficacy results
Within-group analyses using repeated measure ANOVA 
demonstrated that in the topiramate group there are 
significant differences of the Y-BOCS (P < 0.001) and 
the CGI-S scale score (P < 0.001) during the study but not 
Table 1: Comparison of baseline characteristics 
in topiramate and placebo groups
Characteristics SRI + topiramate SRI + placebo P
Age (year) 34.75±10.68 33.40±8.59 0.70*
Duration of OCD (year) 9.50±5.54 8.40±5.52 0.58*
Sex, n (%)
Male 1 (6.3) 1 (6.7) 1.00**
Female 15 (93.8) 14 (93.3)
Marital status, n (%)
Married 13 (81.3) 11 (73.3) 0.68**
Unmarried 3 (18.8) 4 (26.7)
*t-test; **Chi-square test; SRI = Serotonin reuptake inhibitor; OCD = Obsessive-
compulsive disorder
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in the CGI-I (P = 0.121). However, in the placebo group, 
within-group differences were not significant for Y-BOCS 
and CGI-I but was significant for CGI-S (P = 0.020).
Pairwise analyses of changes for each time point are 
reviewed in Table 2. As shown, improvement in the Y-BOCS 
in the topiramate group was significantly different from 
that of the placebo group at the end of week 4 (P = 0.01) 
and especially at the end of week 8 (P = 0.01), but not at the 
study end point [P = 0.058, Figure 2]. The difference in CGI-S 
scale score was statistically significant in week 8 (P = 0.009), 
but not in week 12 (P = 0.052).
To use all the data and adjust effects of dropping outs, we 
used EM algorithm to missing value imputation; the results 
weren’t different.
Full clinical response in the topiramate group was 53.84% 
(7/13) but in the placebo group, two patients (14.28%) had full 
clinical response, this was not statistically significant (P = 0.054).
Safety and tolerability
Topiramate was not well tolerated by some patients. The 
adverse effects reported during the study were renal stone 
(n = 1), paresthesia (n = 5), micturation frequency (n = 2), 
decreased appetite (n = 1), weight loss (n = 3), cognitive 
problems (n = 3) in the topiramate group and gastrointestinal 
disturbance (n = 2) in the placebo group (P > 0.05). At the 
end of month 2, two patients from the topiramate group 
withdrew the trial because of adverse events.
DISCUSSION
This study did not show superior efficacy of topiramate 
over placebo as an add-on agent for treatment-refractory 
OCD. However, reduction of Y-BOCS was significantly 
higher in the topiramate group comparing placebo for 
the first 2 months. Full clinical response in the topiramate 
group was almost significantly higher than a placebo 
group.
As the same with the study performed by Mowla, et al. and 
an open-label case series,[28,31] our finding for the first two, 
emphasize that topiramate may be an useful augmentation 
for patients with refractory OCD; However it wasn’t 
beneficial at the end of our study. In another RCT by Berlin, 
et al. topiramate augmentation was an effective strategy to 
improve compulsions but not obsessions.[32] The opposite 
result was also demonstrated by Ozkara, et al. whereas they 
reported topiramate related OCD.[33]
It is conceivable that the usefulness of topiramate for the 
first 2 months relates to the antianxiety effects of topiramate. 
Unpredictable psycho-social stresses might have been the 
factor to stop the response to the treatment. The inefficacy 
of topiramate at the end of the study might have been a 
temporary phenomenon. If the study had been continued 
for a longer time (a few more months), the efficacy of this 
strategy might have been demonstrated. Higher doses might 
have been necessary to continue the efficacy of topiramate. 
But, since the patients in this study couldn’t tolerate doses 
higher than 200 mg, the usefulness of topiramate wasn’t 
observed at the end of the 3rd month.
About adverse effects, in our study, the most common, but 
not significant side effect was paresthesia. Although Ko, 
et al. trial and Afshar, et al. study showed paresthesia 
was significantly higher in patients taking topiramate 
compared with placebo as adjunctive therapy in 
schizophrenia patients.[34,35]
In our study one patient receiving topiramate, who had full 
clinical response at the end of 2nd month, had to leave the 
study because of renal stone.
Figure 2: Trend of changes of Yale-Brown Obsessive-Compulsive Scale over 
time in topiramate group comparing placebo group
Table 2: Analayses of changes in the OCD symptoms 
severity, improvement indices, in topiramate and 
placebo groups
Scales Topiramate + SRI Placebo + SRI P
Mean SD Mean SD
Y-BOCS score
Baseline 26.75 4.62 26.53 3.31 0.88
Change after 4 weeks 23.94 4.00 26.33 1.26 0.02
Change after 8 weeks 21.32 5.29 25.8 4.33 0.01
Change after 12 weeks 21.45 3.44 24.32 4.50 0.058
CGI-S score
Baseline 6.38 0.65 6.28 0.61 0.31
Change after 8 weeks 4.63 1.18 5.55 0.79 0.009
Change after 12 weeks 4.38 1.15 5.21 1.20 0.052
CGI-I scale score
Week 8 3.00 1.03 3.60 1.05 0.12
Change after 12 weeks 2.31 1.49 3.6 1.10 0.18
SRI = Serotonin reuptake inhibitor; OCD = Obsessive-compulsive disorder; 
SD = Standard deviation; Y-BOCS = Yale-Brown obsessive-Compulsive Scale; 
CGI-S = Clinical global impression-severity; CGI-I = Clinical global impression-
improvement
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One of our study limitations was a high rate of premature 
termination. This is similar to Berlin et al. trial[32] where the 
rate of dropping outs was high too. Other study limitations 
include a small number of cases, short follow duration and 
limited dose of topiramate. Significant results might have 
been observed if the study had included longer follow-up 
and larger sample volume.
Patients did not tolerate doses above 200 mg/day, whereas 
doses up to 400 mg/day had been used in some studies 
before. Likewise, in the Berlin et al. study topiramate was 
not well tolerated, and they had to reduce the dose in about 
39% of patients.[32] Higher doses of topiramate may lead to 
getting more confirmatory results.
CONCLUSION
Although our study didn’t show topiramate as a useful 
option to augment standard treatment in treatment-resistant 
OCD patients, but it may be effective for some patients 
and results are still contradictory and further large-scale 
controlled studies need to prove this.
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